Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - EAGLE PHARMACEUTICALS, INC. | exhibit32110k2019.htm |
| EX-31.2 - EXHIBIT 31.2 - EAGLE PHARMACEUTICALS, INC. | exhibit31210k2019.htm |
| EX-31.1 - EXHIBIT 31.1 - EAGLE PHARMACEUTICALS, INC. | exhibit31110k2019.htm |
| EX-21.1 - EXHIBIT 21.1 - EAGLE PHARMACEUTICALS, INC. | exhibit21110k2019.htm |
| EX-10.35 - EXHIBIT 10.35 - EAGLE PHARMACEUTICALS, INC. | exhibit1035-tymexeagle.htm |
| EX-10.34 - EXHIBIT 10.34 - EAGLE PHARMACEUTICALS, INC. | exhibit1034lily-eaglep.htm |
| EX-10.32 - EXHIBIT 10.32 - EAGLE PHARMACEUTICALS, INC. | exhibit1032fifthamendm.htm |
| EX-4.3 - EXHIBIT 4.3 - EAGLE PHARMACEUTICALS, INC. | exhibit43-descriptiono.htm |
| 10-K - 10-K - EAGLE PHARMACEUTICALS, INC. | egrx10k2019.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Eagle Pharmaceuticals, Inc.
Woodcliff Lake, New Jersey
We hereby consent to the incorporation by reference in the Registration Statement on Form S--3 (Nos. 333-234742 and 333-202592) and Form S-8 (Nos. 333-228876, 333-216839, 333-213683, 333-206729 and 333-194056) of Eagle Pharmaceuticals, Inc. (the “Company”) of our reports dated March 2, 2020, relating to the consolidated financial statements, and the effectiveness of the Company’s internal control over financial reporting, which appear in this Form 10-K.
/s/ BDO USA, LLP
Woodbridge, New Jersey
March 2, 2020